

ASX Announcement

7 May 2024

HALF YEAR INTERIM DIVIDEND ANNOUNCEMENT

EZZ Life Science Holdings Limited (**ASX: EZZ**, or the **Company**), is pleased to announce that after due consideration, the Board has determined the following fully franked interim dividend to shareholders for the half year ending 31 December 2023.

Dividend Timetable

Dividend amount:	\$0.015 per share fully franked
Ex-dividend date:	16 May 2024
Record date:	17 May 2024
Payment date:	17 June 2024

You must be registered as a holder of securities of EZZ on the Record date to be eligible for this dividend. To ensure prompt dividend payments please ensure that the correct bank details have been provided to the registry, Boardroom Pty Limited, prior to the Record date.

This announcement has been authorised by the Board of EZZ Life Science Holdings Limited.

-ENDS-

For further information, please contact:

James Hudson
Corporate Affairs for EZZ Life Science Holdings Limited

P 0467 761 166
E james.hudson@ezzlifescience.com.au

About EZZ Life Science Holdings Limited

EZZ Life Science Holdings Limited (ASX:EZZ) is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on research and development in gene technology to address four key human health challenges: genetic longevity, human papillomavirus (HPV), children's health, and weight management. EZZ Life is passionate about investing in the future of consumer health through the development and distribution of high-quality health and wellness products including functional foods via expansive omnichannel models across Australia, New Zealand, China and worldwide. EZZ Life Science is led by an experienced senior management team that have implemented strategies to drive rapid and ongoing growth of the business.

For more information, please visit our corporate site ezzlifescience.com.au and our consumer site ezzdna.com.au.